X4 Pharmaceuticals (XFOR) Other financing activities (2017 - 2018)

X4 Pharmaceuticals (XFOR) reported Other financing activities of $43000.0 for Q1 2018, down 92.89% quarter-over-quarter from $605000.0 in Q4 2017.

X4 Pharmaceuticals (XFOR) Other financing activities (2017 - 2018) Analysis & Trends

X4 Pharmaceuticals has reported Other financing activities for 2 years, with the latest figure at $43000.0 in Q1 2018.

For the quarter ending Q1 2018, Other financing activities changed N/A year-over-year to $43000.0; the trailing twelve-month figure through Dec 2018 stood at $43000.0 (changed N/A YoY), and the FY2018 full-year result was $43000.0, down 96.93% from the prior year.
Other financing activities for Q1 2018 stood at $43000.0, down from $605000.0 in the prior quarter.
The five-year high for Other financing activities was $605000.0 in Q4 2017, with the low at $43000.0 in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn
9	Abivax	94.37 Bn	94.37 Bn	-
10	X4 Pharmaceuticals	156.06 Mn	156.06 Mn	2.20 Mn

Download Data